Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinorelbine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 7/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 7/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinorelbine SCHEMBL12277732 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL16786345 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL13575786 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL13524297 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL4765 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL10018526 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL23077835 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL18220724 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL21610430 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinorelbine SCHEMBL15113116 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| WO-2020127946-A2 | TUBULIN INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | UNIVERSITÄT BASEL (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| CN-105001243-B | A kind of method that preparing chromatograph in industry purifies vinorelbine | 广州白云山汉方现代药业有限公司 | 2017-07-14 | — | — | CN | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| CN-105001243-A | Method for industrially preparing chromatographically pure vinorelbine | GUANGZHOU HANFANG PHARMACEUTICAL CO LTD | 2015-10-28 | — | — | CN | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| CN-103282777-A | Methods of treating cancer | ENDOCYTE INC | 2013-09-04 | — | — | CN | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2012164060-A1 | METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120308562-A1 | METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| WO-2012065085-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-1915221-B | Liposome of alkaloid in vinca, and preparation method | KANGHAI PHARMACEUTICAL CO LTD NANJING | 2010-09-08 | — | — | CN | disclosed |
| CN-1915221-A | Liposome of alkaloid in vinca, and preparation method | KANGHAI PHARMACEUTICAL CO LTD (CN) | 2007-02-21 | — | — | CN | disclosed |
| EP-1712238-A1 | Anthracyclin induced immunogenic dead or dying cells composition | INSTITUT GUSTAVE ROUSSY (FR) | 2006-10-18 | — | — | EP | disclosed |
| WO-2003045359-A2 | COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER | ASTION ONCOLOGY APS (DK) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | TUBB4A 2739/4885TUBB 1319/4885TUBA3C 2798/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | TUBB4A 1131/4885TUBB 1209/4885TUBA3C 894/4885 |
| US-20120308562-A1 | METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND | MTOR, RICTOR, PIK3CD | TUBB4A 3237/4885TUBB 2810/4885TUBA3C 2266/4885 |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | TUBB4A 3440/4885TUBB 3677/4885TUBA3C 2514/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | TUBB4A 384/4885TUBB 571/4885TUBA3C 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.